Black Diamond Therapeutics, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Black Diamond Therapeutics, Inc. on June 12, 2025. The meeting was conducted in a virtual-only format via live webcast. As of the record date (April 14, 2025), there were 56,676,716 shares of Common Stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on two proposals. A quorum was established with 42,988,581 shares present or represented by proxy.
- Proposal No. 1 (Election of Class II Directors): Three nominees were elected to serve three-year terms until the 2028 annual meeting.
- Garry E. Menzel: Received 33,533,241 votes FOR, 956,676 WITHHELD, and 8,498,664 BROKER NON-VOTES.
- Ali Behbahani: Received 14,529,061 votes FOR, 19,960,856 WITHHELD, and 8,498,664 BROKER NON-VOTES.
- Samarth Kulkarni: Received 14,217,936 votes FOR, 20,271,981 WITHHELD, and 8,498,664 BROKER NON-VOTES.
- Proposal No. 2 (Ratification of Auditors): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
- Results: 42,483,483 FOR, 445,873 AGAINST, 59,225 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the significant number of "Withheld" votes for nominees Ali Behbahani and Samarth Kulkarni, which exceeded the "For" votes for each.
- Confirm the total number of Broker Non-Votes (8,498,664) which represented a substantial portion of the outstanding shares.
- Note that the company is classified as an "Emerging Growth Company."
- Confirm the fiscal year end date of December 31, 2025, for the ratified auditor appointment.